Following the approval of the first antiangiogenic agent bevacizumab for NSCLC therapy in 2006, intensive efforts were performed to screen for predictors of response to improve the clinical outcome of antiangiogenic drugs.6 Unfortunately, to date, no predictor has yet been validated for response to antiangiogenic drugs in NSCLC, although some predictors showed potential including neuropilin‐1 and VEGFR‐1 expression, short VEGF‐A isoform levels, and genetic alterations in VEGF‐A or VEGFR, among others.6, 7. This evidence concerns the gene FLT1 and non-small cell lung carcinoma.